Our Research
The Rossy PSP clinical program is currently leading a wide range of research studies to enhance our current understanding of Progressive Supranuclear Palsy:
- Bloodwork and Risk Factor Questionnaire Study
- Detection of peripheral disease-associated pathological proteins as Diagnostic Markers for Parkinsonian Disorders
- The use of [18F]MK-6240, as an in vivo proxy of tau protein deposition in progressive supranuclear palsy (PSP), cortical-basal-degeneration (CBD) and Parkinson's disease dementia (PDD)
- Utilization of novel PET radioligand (18F-SDM-8) for imaging synaptic vesicle glycoprotein 2A (SV2A) as an in vivo proxy of synaptic density
- Using various MRI measures to better capture the neural substrate of cognitive, behavioural and motor impairment in PSP and other neurodegenerative diseases
- Using PET Tau PI-2620, a novel tau PET ligand to better detect Tau in PSP and track changes in the brain over time
- Using a combination of biofluid and imaging biomarkers to make an earlier diagnosis of PSP and track disease progression
- Evaluating inflammatory markers and their role in PSP. The aim of this study is to better understand the role of neuroinflammation in PSP
- Understanding the pathological involvement of the earliest vulnerable brain regions in PSP
- Comparative studies of neuropathological and neuroimaging observations
- Evaluating the distribution of disease-associated proteins in the human brain affected by PSP and related conditions and their interaction with each other
- Application of protein seeding assays to detect disease-associated proteins in body fluids, skin biopsy samples and post-mortem brain
Recent Poster Presentations
Couto, B., Fox, S., Tartaglia, M., Rogaeva, E., Antwi, J., Bhakta, P., Kovacs, G., Lang, A. (2023). The Rossy Progressive Supranuclear Palsy Centre: Creation and Initial Experience. Canadian Journal of Neurological Sciences, 1-8. doi:10.1017/cjn.2022.332
